HPV-associated oropharyngeal cancer

Sheedy, Trina; Heaton, Chase M.

doi:10.1097/01.jaa.0000578756.52642.cb

Cited by 19 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HPV vaccine has been effective at reducing the prevalence of HPV infection, including the high-risk HPV types 16 and 18 associated with oropharyngeal cancer (OPC) [ 6 ]. However, adherence to HPV vaccination guidelines from the Advisory Committee on Immunization Practices (ACIP) has been challenging.…”

Section: Introductionmentioning

confidence: 99%

Dental Students’ Knowledge and Attitudes about Human Papillomavirus Prevention

et al. 2021

View full text Add to dashboard Cite

The purpose of the current study was to assess knowledge and attitudes about human papillomavirus (HPV) and HPV vaccination for oropharyngeal cancer (OPC) prevention in first-year through fourth-year dental students. Methods: In this cross-sectional quantitative study, surveys assessed knowledge and attitudes about HPV, HPV-related OPC, and HPV vaccination of incoming first-year dental students (D1), outgoing first- and second-year dental students (D1–D2), and outgoing third- and fourth-year dental students (D3–D4). After completing a 40-item pre-training knowledge and attitude assessment survey, a one-time, one-hour national HPV training session was conducted. An 8-item attitudinal post-survey was completed after training. Results: Of 173 participants (75.9% response rate), over 85% did not know that the rate of HPV is not highest among women in their 30s, and only 11% to 28% knew that smoking-associated OPC is more deadly than HPV-associated OPC. While participants overall expressed willingness to administer the HPV vaccine, the willingness of dental students to do so in their future practice tapered off progressively through dental school year categories (p < 0.001). Among outgoing D1–D4 students, the one-hour HPV training increased participants’ self-perceived ability to describe the burden of HPV disease, discuss the importance of HPV vaccination for cancer prevention, and provide needed HPV vaccination information to parents (all p ≤ 0.004). Conclusions: Understanding deficits in dental student knowledge and attitudes across the 4 years of dental school may help dental educators better understand the timing and content needed for effective HPV training in the dental school curriculum to reduce HPV-associated OPC prevalence.

show abstract

Section: Introductionmentioning

confidence: 99%

Dental Students’ Knowledge and Attitudes about Human Papillomavirus Prevention

et al. 2021

View full text Add to dashboard Cite

show abstract

“…15 Given that its incidence has been steadily increasing in high-income countries, to the point that it has surpassed that of cervical cancer, action needs to be taken on a global scale for its mitigation. 16 Because HPV-related OPC has no, to our knowledge, premalignant lesion to act as a proxy event/end point in vaccine clinical trials, high-quality proof that its clinical, albeit early, precursor, HPV16 infection, can be prevented through HPV vaccines is of paramount importance. 4,5 Despite knowing that men can also suffer from severe consequences of HPV infections (we have come a long way since the first establishment of the HPV-cervical cancer relationship), vaccination against HPV remains, if not strictly, then primarily, a "female business."…”

Section: Discussionmentioning

confidence: 99%

Human Papillomavirus Vaccine to End Oropharyngeal Cancer. A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Oropharyngeal cancer (OPC) is currently the most frequent human papillomavirus (HPV)-related malignancy in high-income countries. Oral HPV16 infection is the cause of HPV-related OPC in more than 90% of cases and is primarily (90%) linked to oral sex. This systematic review and meta-analysis aimed at comparing the prevalence of oral vaccine-type HPV infection in individuals vaccinated with HPV vaccines and unvaccinated controls. Three databases (MEDLINE, ScienceDirect, and the Cochrane Library), as well as other sources, were searched by 2 independent reviewers. Controlled studies testing the efficacy or effectiveness of licensed HPV vaccines were included. The primary end point was multiple oral HPV infections in one individual with low-risk and high-risk types. Secondary end point was the number of oral HPV16 infections. Six studies-2 randomized controlled trials and 4 cross-sectional studies-with a total of 15,240 participants were included in a meta-analysis, which showed that vaccinated individuals were 46% (risk ratio, 0.54; 95% confidence interval, 0.32-0.91) less likely to develop oral vaccine-type HPV infection (P = 0.02). A second meta-analysis of 4 studies (1 randomized controlled trial and 3 cross-sectional studies) and 13.285 participants showed 80% (risk ratio, 0.20; 95% confidence interval, 0.09-0.43) less likelihood of oral HPV16 infection (P < 0.0001). This study suggests that HPV vaccines can protect against oral vaccine-type HPV infection including high-risk HPV16 infection, thus reducing the incidence of HPV-related OPC. Vaccination against HPV, especially in males, who are predominantly affected by HPV-related OPC, could result in the prevention of this disease.

show abstract

“…For locoregionally advanced-stage disease (T3-4, N1-3, or fixed/matted nodes), systemic therapies are often integrated as part of a multimodality approach to potentiate the effect of definitive local/regional treatments. [10][11][12] In the incurable recurrent or metastatic setting, drug therapies are utilized to palliate symptoms, optimize disease control, and prolong survival.…”

Section: General Principles Of Systemic Therapy For Hpv-related Oropharyngeal Cancermentioning

confidence: 99%

Therapeutic strategies for systemic therapies of human papillomavirus‐related oropharyngeal cancer

Hung

Pfister

2021

Journal of Surgical Oncology

View full text Add to dashboard Cite

Our understanding of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) and its molecular basis continues to evolve and produce important insights into customized therapeutic strategies. Novel therapeutics exploiting HPV-related targets are being evaluated in the incurable setting, while the favorable prognosis of locoregionally advanced disease has stimulated investigation into de-escalation strategies. There is much opportunity for better personalization of standard therapy according to HPV status. This review discusses both current and investigational therapeutic strategies for HPV-related OPC.

show abstract

HPV-associated oropharyngeal cancer

Cited by 19 publications

References 21 publications

Dental Students’ Knowledge and Attitudes about Human Papillomavirus Prevention

Dental Students’ Knowledge and Attitudes about Human Papillomavirus Prevention

Human Papillomavirus Vaccine to End Oropharyngeal Cancer. A Systematic Review and Meta-Analysis

Therapeutic strategies for systemic therapies of human papillomavirus‐related oropharyngeal cancer

Contact Info

Product

Resources

About